<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1052243361488264&amp;ev=PageView&amp;noscript=1">

Flow Cytometry Blog

Preclinical Toxicology and Clinical Studies - Using Flow Cytometry throughout Development

Posted on: November 13, 2019

The pursuit of better medicine may take many years because of the complicated and often indirect path of biomedical research. Do you find yourself confused or unclear about when to use flow cytometry in “bench-to-bedside” research? The key is to understand the differences between preclinical and clinical research.

Read The Entire Blog Post »

Posted in ,

Cytokine Release Syndrome and CAR-T cells: Challenges to Cutting-Edge Therapies

Posted on: November 07, 2019

Personalized cancer treatments, particularly chimeric antigen receptor (CAR) T cell therapy, have revolutionized the treatment of blood cancers and solid tumors. CAR T cell-based treatments use genetically modified T cells from a patient that are engineered to express a modified T cell receptor, which includes an extracellular binding domain that binds specifically to a patient’s tumor antigen, a transmembrane domain, and an intracellular domains that has multiple costimulatory domains (i.e., CD28, 4-1BB). Patients typically undergo lymphodepletion chemotherapy and are infused with their specific CAR -T cells, which are activated upon encounter with tumor antigen and can proliferate and lyse tumor cells. Although this type of treatment has been shown to be very effective for treating a wide range of tumors, severe side effects can occur, including cytokine release syndrome (CRS). Flow cytometry is a critical tool for understanding CRS and identifying biomarkers that may predict the onset of this complication.

Read The Entire Blog Post »

Posted in ,

3 Tips For Hybridoma Development

Posted on: October 30, 2019

Hybridoma Development to create custom monoclonal antibodies is a multiphase process and with all the new technologies available to the scientist, the overall process might be a little overwhelming. Although hybridoma development cannot really be described as a black art, there are several important steps that can really impact the outcome of your monoclonal antibody production and even though the process of PEG fusion is fairly straight forward, imposing a common sense approach can make a difference.

Read The Entire Blog Post »

Posted in

Why Outsource Flow Cytometry?

Posted on: October 29, 2019

Make Your Decision With These 5 Questions

You have just gotten approval to start a big phase 1 clinical trial and 172 precious blood samples are about to come through your door in about two months. What do you do? Do you clone yourself and your outstanding flow cytometry skills? Do you consider skipping sleep for a few weeks? Do you panic? Perhaps, you should consider outsourcing your flow cytometry analysis ...

Read The Entire Blog Post »

Posted in , , ,

Receptor Occupancy (RO) Explained

Posted on: October 23, 2019

Many biologic therapeutics currently on the market or in development work by binding to a specific cell surface receptor. These therapeutics are typically stand-alone monoclonal antibodies, or antibodies conjugated with a second therapeutic component. One of the key analyses for determining the efficacy and therapeutic dose of these types of biologic therapeutics is the so-called receptor occupancy (RO) assay. Flow cytometry-based RO assays are a powerful and rapid method that can be customized to your cell type and therapeutic molecule of interest. Check out these four basic approaches to RO assays and learn how they may advance your research.

Read The Entire Blog Post »

Posted in

T Cell Exhaustion in Immuno-oncollogy
 

Recent Blog Posts

Receive Updates By Email

Computational Cytometry | Flow Cytometry Data Analysis in the Era of Quantitative Data Science
Download Accelerated CAR T Cell Therapy with Flow Cytometry
Flow Cytometry & Immunology Research
Flow Cytometry for Clinical Trials